CL2023000004A1 - Formulación en concentración alta de proteínas de unión a antígeno del factor xii - Google Patents

Formulación en concentración alta de proteínas de unión a antígeno del factor xii

Info

Publication number
CL2023000004A1
CL2023000004A1 CL2023000004A CL2023000004A CL2023000004A1 CL 2023000004 A1 CL2023000004 A1 CL 2023000004A1 CL 2023000004 A CL2023000004 A CL 2023000004A CL 2023000004 A CL2023000004 A CL 2023000004A CL 2023000004 A1 CL2023000004 A1 CL 2023000004A1
Authority
CL
Chile
Prior art keywords
antigen binding
factor xii
formulation
high concentration
binding proteins
Prior art date
Application number
CL2023000004A
Other languages
English (en)
Spanish (es)
Inventor
Johnston Michael
Grace Goodall Dianna
Aaron Edwards Nathan
Original Assignee
CSL Innovation Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Innovation Pty Ltd filed Critical CSL Innovation Pty Ltd
Publication of CL2023000004A1 publication Critical patent/CL2023000004A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2023000004A 2020-07-03 2023-01-03 Formulación en concentración alta de proteínas de unión a antígeno del factor xii CL2023000004A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20184004 2020-07-03

Publications (1)

Publication Number Publication Date
CL2023000004A1 true CL2023000004A1 (es) 2023-08-25

Family

ID=71514949

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000004A CL2023000004A1 (es) 2020-07-03 2023-01-03 Formulación en concentración alta de proteínas de unión a antígeno del factor xii

Country Status (12)

Country Link
US (1) US20240277839A1 (enExample)
EP (1) EP4175669A4 (enExample)
JP (1) JP7880827B2 (enExample)
KR (1) KR20230035355A (enExample)
CN (1) CN116322764A (enExample)
AU (1) AU2021302684A1 (enExample)
BR (1) BR112022026482A2 (enExample)
CA (1) CA3183508A1 (enExample)
CL (1) CL2023000004A1 (enExample)
IL (1) IL298989A (enExample)
MX (1) MX2022016365A (enExample)
WO (1) WO2022000046A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4337257A1 (en) * 2021-05-12 2024-03-20 AnaptysBio, Inc. Antibody composition
US20250042984A1 (en) * 2021-12-20 2025-02-06 CSL Innovation Pty Ltd Protein formulations and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250164T1 (hr) 2011-07-22 2025-04-11 Csl Behring Gmbh Inhibitorna monoklonska antitijela protiv faktora xii/xiia i njihove uporabe
JP5859148B2 (ja) * 2012-03-08 2016-02-10 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Aβ抗体製剤
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
EP3325516B1 (en) * 2015-07-21 2021-12-15 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor xiia
EP3433274A1 (en) * 2016-03-25 2019-01-30 Visterra, Inc. Formulation of antibody molecules to dengue virus
EP3440107A4 (en) * 2016-04-06 2020-02-19 CSL Limited METHOD FOR TREATING ATHEROSCLEROSIS
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
BR112019011900A2 (pt) 2016-12-23 2019-11-26 Serum Institute Of India Private Limited métodos melhorados para aumentar a produtividade de anticorpos na cultura de células de mamíferos e minimizar a agregação durante os processos downs-tream, processos de formulação, e formulações de anticorpos estáveis obtidas dos mesmos
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
EA202190056A1 (ru) * 2018-06-19 2021-05-28 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ
US12134657B2 (en) 2018-11-28 2024-11-05 Oregon Health & Science University Therapeutic factor XII antibody
US20230390418A1 (en) * 2020-10-29 2023-12-07 Regenxbio Inc. Vectorized factor xii antibodies and administration thereof

Also Published As

Publication number Publication date
WO2022000046A1 (en) 2022-01-06
CA3183508A1 (en) 2022-01-06
KR20230035355A (ko) 2023-03-13
AU2021302684A1 (en) 2023-02-23
EP4175669A1 (en) 2023-05-10
BR112022026482A2 (pt) 2023-01-31
JP7880827B2 (ja) 2026-06-26
MX2022016365A (es) 2023-01-30
US20240277839A1 (en) 2024-08-22
EP4175669A4 (en) 2025-11-12
JP2023531315A (ja) 2023-07-21
CN116322764A (zh) 2023-06-23
IL298989A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
ES2569409T3 (es) Composiciones de anticuerpo anti-CTLA-4
ES2548238T3 (es) Formulaciones antagonistas de VEGF
ECSP19062769A (es) Formulación de anticuerpo monoclonal anti-vrs
PE20060552A1 (es) Composicion de anticuerpo her2
BR112021013337A2 (pt) Proteínas de ligação a patógenos
AR111773A1 (es) Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración
PE20190469A1 (es) Formulaciones, kits y metodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados
CO5660273A2 (es) Formulaciones de proteina y anticuerpo de alta concentracion
CL2024003891A1 (es) Anticuerpo multiespecífico; composición farmacéutica; y su uso.
MX2024000901A (es) Composiciones y metodos para la degradacion selectiva de proteinas dise?adas por ingenieria.
CO2019009480A2 (es) Composición farmacéutica de bajo ph que comprende construcciones de anticuerpos que activan linfocitos t
AR079836A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r)
BRPI0713421A2 (pt) Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
AR090272A1 (es) FORMULACION DE ANTICUERPOS Ab
AR089787A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-ang2
EA202193240A1 (ru) Стабилизированные составы, содержащие анти-angptl3 антитела
MX2019000898A (es) Amortiguador de lavado de cromatografia de afinidad.
AR093641A1 (es) Eliminacion de celulas de cancer por celulas t citotoxicas circulantes especificas de virus utilizando proteinas multifuncion que comprenden cmh de clase i con diana en celulas de cancer
CR20210318A (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
BR112022012768A2 (pt) Formulação de anticorpo de receptor 1 de morte celular programada e uso da mesma
MX2022016365A (es) Formulacion de alta concentracion de proteinas de union a antigeno de factor xii.
AR118853A1 (es) Formulaciones farmacéuticas que contienen proteínas de fusión fc de dominio extracelular de cd80
BRPI0910509B8 (pt) uso do anticorpo, anticorpo e composição farmacêutica
CO2026004975A2 (es) Agentes de unión a albúmina bivalentes y multivalentes
CO2024013582A2 (es) Formulación liofilizada que comprende una proteína de fusión que incluye α-galactosidasa a